Home > Insider Trading > Filing (0001209191-13-047411)

Filing Details

Accession Number:: 0001209191-13-047411
Form Type:: 4/A
Zero Holdings:: No
Publication Time:: 2013-10-03 20:11:07
Reporting Period:: 2013-08-13

Filing Date:: 2013-10-03
Accepted Time:: 2013-10-03 20:11:07
Original Submission Date:: 2013-08-15
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
949858	Oncogenex Pharmaceuticals Inc.	OGXI	In Vitro & In Vivo Diagnostic Substances (2835)	954343413

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1568605	D. Susan Wyrick	1522 217Th Place Se Suite 100 Bothell WA 98021	Pao	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2013-08-19	194	$8.68	481	No	4	S	Direct
Common Stock	Acquisiton	2013-10-01	688	$0.00	1,169	No	4	M	Direct
Common Stock	Disposition	2013-10-02	191	$9.04	978	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Unit (RSU)	Disposition	2013-10-01	688	$0.00	688	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2,062		2016-07-29	No	4	M	Direct

Footnotes

This amended Form 4 is filed to correct the transaction date, which was previously inadvertently reported as August 13, 2013.
This amended Form 4 is filed to correct the transaction code, which was previously inadvertently reported as "F". The sales reported on this amended Form 4 were made for the sole purpose of covering the reporting person's tax liability in connection with the settlement of RSUs on August 13, 2013, which transaction was previously reported.
This amended report is filed to correct the number of shares disposed of in connection with the sale of shares to satisfy the reporting person's tax liability in connection with the settlement of RSUs on August 13, 2013, which transaction was previously reported.
Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II.
This amended Form 4 is filed to correct the transaction code, which was previously inadvertently reported as "F". The sales reported on this amended Form 4 were made for the sole purpose of covering the reporting person's tax liability in connection with the settlement of the RSUs listed in Table II.
This amended report is filed to correct the number of shares disposed of in connection with the sale of shares to satisfy the reporting person's tax liability in connection with the settlement of the RSUs listed in Table II.
Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock at settlement.
Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of (i) each anniversary of June 29, 2012 and (ii) the first day thereafter during which the issuer's trading window is open.